Background: Multiple sclerosis (MS) and Neuromyelitis optica (NMO) are inflammatory and demyelinating diseases of the central nervous system (CNS). NK cells are supposed to play an important role in the pathophysiology of MS, but their role in the NMO remains unknown. The aim of this study was to compare the prevalence of different subpopulations of NK cells in the patients with MS and NMO and healthy individuals. Methods: Treatment Naive MS and NMO patients, age, and sex matched controls were included in this study. PBMCs were isolated from peripheral blood and different phenotypes of circulating NK cells were compared with the flow cytometry analysis. Results: There were no significant differences in the mean percentages of circulating NK...
BACKGROUND AND OBJECTIVES: Inhibition of terminal complement in neuromyelitis optica spectrum disord...
BACKGROUND: Natural killer (NK) cells may play a role in multiple sclerosis (MS). Ratios of NK cells...
CD56bright natural killer cells and response to daclizumab HYP in relapsing-remitting MS Objective: ...
Background: Multiple sclerosis (MS) and Neuromyelitis optica (NMO) are inflammatory and demyelinatin...
This thesis addresses the hypothesis that multiple sclerosis (MS) patients have an imbalance in the ...
Recent evidence has shown that CD56bright NK cells, a subset of NK cells abundant in lymph nodes, ma...
Background: Previous studies have reported impaired cytotoxic activity in Natural Killer (NK) CD56Di...
Multiple sclerosis (MS) is assumed to be an autoimmune disease initiated by autoreactive T cells tha...
Immunological profile of multiple sclerosis patients Abstrakt Multiple sclerosis is an autoimmune ne...
Multiple sclerosis (MS), is a chronic inflammatory disease of central nervous system with unclear et...
NK cells are multicompetent lymphocytes of the innate immune system with a central role in host defe...
Background Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous syst...
There is increasing evidence that natural killer (NK) cells exhibit regulatory features. Among them,...
As the most common non-traumatic disabling disease among adolescents, multiple sclerosis (MS) is a d...
Background and purpose: Natural killer (NK) cells may play a role in multiple sclerosis (MS). Ratios...
BACKGROUND AND OBJECTIVES: Inhibition of terminal complement in neuromyelitis optica spectrum disord...
BACKGROUND: Natural killer (NK) cells may play a role in multiple sclerosis (MS). Ratios of NK cells...
CD56bright natural killer cells and response to daclizumab HYP in relapsing-remitting MS Objective: ...
Background: Multiple sclerosis (MS) and Neuromyelitis optica (NMO) are inflammatory and demyelinatin...
This thesis addresses the hypothesis that multiple sclerosis (MS) patients have an imbalance in the ...
Recent evidence has shown that CD56bright NK cells, a subset of NK cells abundant in lymph nodes, ma...
Background: Previous studies have reported impaired cytotoxic activity in Natural Killer (NK) CD56Di...
Multiple sclerosis (MS) is assumed to be an autoimmune disease initiated by autoreactive T cells tha...
Immunological profile of multiple sclerosis patients Abstrakt Multiple sclerosis is an autoimmune ne...
Multiple sclerosis (MS), is a chronic inflammatory disease of central nervous system with unclear et...
NK cells are multicompetent lymphocytes of the innate immune system with a central role in host defe...
Background Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous syst...
There is increasing evidence that natural killer (NK) cells exhibit regulatory features. Among them,...
As the most common non-traumatic disabling disease among adolescents, multiple sclerosis (MS) is a d...
Background and purpose: Natural killer (NK) cells may play a role in multiple sclerosis (MS). Ratios...
BACKGROUND AND OBJECTIVES: Inhibition of terminal complement in neuromyelitis optica spectrum disord...
BACKGROUND: Natural killer (NK) cells may play a role in multiple sclerosis (MS). Ratios of NK cells...
CD56bright natural killer cells and response to daclizumab HYP in relapsing-remitting MS Objective: ...